SenzaGen AB

Activities: Regulatory Analysis Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

SenzaGen and MB Research Labs sign toxicology agreement

With new legislature, animal-free <em>in vitro</em> toxicological testing is a growing market in the US. This collaboration taps into this market
Analysis

Next-generation safety testing

In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Pharmaceutical

Swedish SenzaGen teams up with Chinese animal-free testing specialist

The partnership comes at a time when a ban on animal experiments is expected

SenzaGen strengthens its organisation with IR and communications director
Recruitment

SenzaGen recruits Business Development Director
Research & Development

Collaboration tackles respiratory irritancy hazard

SenzaGen and AstraZeneca will develop a new genomic signature to distinguish allergens from irritants in the respiratory tract
Subscribe now